Naar www.iknl.nl
- Mamma > borstkanker2017
Notificatie richtlijn E-mail richtlijn Naar startpagina oncoline
----------

Versie: 1.0, Redactionele aanpassing 2018-07-02 , Verantwoording: NABON, Type: Landelijke richtlijn

Referentielijst

1 - Aalders KC (2016)
Aalders KC, Postma EL, Strobbe LJ, et al. Contemporary Locoregional Recurrence Rates in Young Patients With Early-Stage Breast Cancer. J Clin Oncol. 2016 Jun 20;34(18):2107-14. doi: 10.1200/JCO.2015.64.3536. Epub 2016 Mar 14.
 
2 - Aalders KC (2016)
Aalders KC, van Bommel AC, van Dalen T, et al. Contemporary risks of local and regional recurrence and contralateral breast cancer in patients treated for primary breast cancer. Eur J Cancer. 2016 Aug;63:118-26. doi: 10.1016/j.ejca.2016.05.010. Epub 2016 Jun 11.
 
3 - Adank MA et al (2015)
Adank MA et al. CHEK2-mutation in Dutch breast cancer families: expanding genetic testing for breast cancer. Ned Tijdschr Geneeskd. 2015;159:A8910.
 
4 - Adank MA et al (2013)
Adank MA et al. Excess breast cancer risk in first degree relatives of CHEK2*1100delC positive familial breast cancer cases. Eur J Cancer. 2013 May;49(8):1993-9. doi: 10.1016/j.ejca.2013.01.009.
 
5 - Adank MA (2011)
Adank MA, Jonker MA, Kluijt I, et al. CHEK2*1100delC homozygosity is associated with a high breast cancer risk in women. J Med Genet. 2011 Dec;48(12):860-3.
 
6 - Al-Mubarak M (2014)
Al-Mubarak M, Tibau A, Templeton AJ, et al. Extended adjuvant tamoxifen for early breast cancer: a meta-analysis. PloS one. 2014; 9: e88238. PMC3930532.
 
7 - An et al (2014)
An et al. Diagnostic performance of 18F-FDG PET/CT, ultrasonography and MRI. Detection of axillary lymph node metastasis in breast cancer patients. Nuklearmedizin. 2014;53(3):89-94.
 
8 - Ando M et al (2014)
Ando M et al, Randomized phase II study of weekly paclitaxel with and without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA breast cancer without HER2 overexpression. Breast Cancer Res Treat. 2014 Jun;145(2):401-9.
 
9 - Antoniou AC et al (2014)
Antoniou AC et al. Breast-cancer risk in families with mutations in PALB2. N Engl J Med. 2014 Aug 7;371(6):497-506.
 
10 - Bane AL (2014)
Bane AL, Whelan TJ, et al. Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Ann Oncol. 2014 May;25(5):992-8.
 
11 - Basu NN (2015)
Basu NN, Ingham S, et al. Risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a 30-year semi-prospective analysis. Fam Cancer. 2015 Dec;14(4):531-8. doi: 10.1007/s10689-015-9825-9.
 
12 - Baum M (2006)
Baum M, Hackshaw A, Houghton J, et al. Adjuvant goserelin in pre-menopausal patients with early breast cancer: results from the ZIPP study. Eur J Canceer 2006; 42: 895-904.
 
13 - Bear HD (2003)
Bear HD, Anderson S, Brown A, et al; National Surgical Adjuvant Breast and Bowel Project Protocol B-27. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J ClinOncol. 2003 Nov 15;21(22):4165-74.
 
14 - Benson JR (2013)
Benson JR, Wishart GC. Predictors of recurrence for ductal carcinoma in situ after breast-conserving surgery. Lancet Oncol. 2013 Aug;14(9):e348-57. doi: 10.1016/S1470-2045(13)70135-9.
 
15 - Bernsdorf M (2012)
Bernsdorf M, Berthelsen AK, Wielenga VT, et al. Preoperative PET/ CT in early-stage breast cancer. Ann Oncol 2012;23(9):2277–82. http://dx.doi.org/10.1093/annonc/mds002.
 
16 - Binkhorst L ea (2015)
Binkhorst L ea. Augmentation of endoxifen exposure in tamoxifen-treated women following SSRI-switch. Clin Pharmacokinet. DOI 10.1007/s40262-015-0315-x. Published on line 08 October 2015.
 
17 - Blamey RW (2013)
Blamey RW, Bates T, Chetty U, et al. Radiotherapy or tamoxifen after conserving surgery for breast cancers of excellent prognosis: British Association of Surgical Oncology (BASO) II trial. Eur J Cancer. 2013 Jul;49(10):2294-302. doi: 10.1016/j.ejca.2013.02.031. Epub 2013 Mar 21.
 
18 - Bliss J et al (2007)
Bliss J et al. Ovarian ablation or suppression in premenopausal early breast cancer: results from the international adjuvant breast cancer ovarian ablation or suppression group. J Nat Cancer Inst 2007; 99: 516-25.
 
19 - Blok E et al (2017)
Blok E et al. Optimal duration of extended adjuvant endocrine therapy for early breast cancer: results of the IDEAL trial. JNCO 2017 in press.
 
20 - Blok EJ (2015)
Blok EJ, Derks MG, van der Hoeven JJ, van de Velde CJ, Kroep JR. Extended adjuvant endocrine therapy in hormone-receptor positive early breast cancer: current and future evidence. Cancer Treat Rev. 2015 Mar;41:271-6
 
21 - Boileau JF (2015)
Boileau JF, Poirier B, Basik M et al. Sentinel Node Biopsy After Neoadjuvant Chemotherapy in Biopsy-Proven Node-Positive Breast Cancer: The SN FNAC Study. J Clin Oncol. 2015 Jan 20;33(3):258-64. doi: 10.1200/JCO.2014.55.7827. Epub 2014 Dec 1
 
22 - Borges S (2006)
Borges S. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. ClinPharmacolTher 2006;80:61-74
 
23 - Boughey JC (2016)
Boughey JC, Ballman KV, Le-Petross HT, et al. Identification and Resection of Clipped Node Decreases the False-negative Rate of Sentinel Lymph Node Surgery in Patients Presenting With Node-positive Breast Cancer (T0-T4, N1-N2) Who Receive Neoadjuvant Chemotherapy: Results From ACOSOG Z1071 (Alliance). Ann Surg. 2016 Apr;263(4):802-7.
 
24 - Boughey JC (2015)
Boughey JC, Suman VJ, Mittendorf EA, et al; Alliance for Clinical Trials in Oncology. Factors affecting sentinel lymph node identification rate after neoadjuvant chemotherapy for breast cancer patients enrolled in ACOSOG Z1071 (Alliance). Ann Surg. 2015 Mar;261(3):547-52.
 
25 - Boughey (2013)
Boughey, Suman, Mittendorf et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with lymph node-positive breast cancer. The ACOZOG Z1071(Alliance) clinical trial. JAMA, 2013, Oct 9, 310 (14); 1455-61
 
26 - Burstein HJ (2016)
Burstein HJ, Lacchetti C, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline update on ovarian suppression. J Clin Oncol 2016; 34: 1-15.
 
27 - Buzdar AU (2005)
Buzdar AU. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J ClinOncol 2005;23:3676-85
 
28 - Cameron D et al (2017)
Cameron D et al. Lancet 2017. 11 year´s follow up of trastuzumab after adjuvant chemotherapy in HER2 positive early breast cancer etc.
 
29 - Cardoso F (2016)
Cardoso F, van't Veer LJ, Bogaerts J, et al. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. N Engl J Med. 2016 Aug 25;375(8):717-29. doi: 10.1056/NEJMoa1602253.
 
30 - Caudle AS (2016)
Caudle AS, Yang WT, Krishnamurthy S, et al. Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection. J ClinOncol. 2016 Apr 1;34(10):1072-8.
 
31 - Caudle AS (2015)
Caudle AS, Yang WT, Mittendorf EA, et al. Selective surgical localization of axillary lymph nodes containing metastases in patients with breast cancer: a prospective feasibility trial. JAMA Surg. 2015;150(2):137-43.
 
32 - Caudle AS (2012)
Caudle AS, Yu TK, Tucker SL, et al. Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy. Breast Cancer Res. 2012 May 23;14(3):R83.
 
33 - Chagpar AB (2015)
Chagpar AB, Killelea BK, Tsangaris TN, et al. A Randomized, Controlled Trial of Cavity Shave Margins in Breast Cancer. N Engl J Med. 2015 Aug 6;373(6):503-10. doi: 10.1056/NEJMoa1504473. Epub 2015 May 30
 
34 - Chai X (2015)
Chai X, Domchek S, Kauff N, et al. RE: Breast Cancer Risk After Salpingo-Oophorectomy in Healthy BRCA1/2 Mutation Carriers: Revisiting the Evidence for Risk Reduction. J Natl Cancer Inst. 2015 Aug 11;107(9). pii: djv217. doi: 10.1093/jnci/djv217. Print 2015 Sep.
 
35 - Chan A (2016)
Chan A, Buyse M, Yao B. Neratinib after trastuzumab in patients with HER2-positive breast cancer - Author's reply. Lancet Oncol. 2016 May;17(5):e176-7.
 
36 - Chavez-MacGregor M (2013)
Chavez-MacGregor M, Zhang N, Buchholz TA, et al. Hortobagyi GN, Giordano SH. Trastuzumab-related cardiotoxicity among older patients with breast cancer. J Clin Oncol. 2013 Nov 20;31(33):4222-8.
 
37 - Clézardin P (2005)
Clézardin P, Ebetino FH, Fournier PG. Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity. Cancer Res. 2005 Jun 15;65(12):4971-4.
 
38 - Coates AS (2015)
Coates AS, Winer EP, Goldhirsch A, et al. Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the primary therapy of early breast cancer 2015. Ann Oncol 2015; 26: 1533-46.
 
39 - Cochet A (2014)
Cochet A, Dygai-Cochet I, Riedinger JM, et al. ¹8F-FDG PET/CT provides powerful prognostic stratification in the primary staging of large breast cancer when compared with conventional explorations. Eur J Nucl Med Mol Imaging. 2014 Mar;41(3):428-37.
 
40 - Coleman R (2014)
Coleman R, Body JJ, Aapro M, et al; on behalf of the ESMO Guidelines Working Group: Bone health in cancer patients: ESMO Clinical Practice Guidelines. Annals of Oncology 25 (Supplement 3): iii124–iii137, 2014.
 
41 - Coleman R (2013)
Coleman R, de Boer R, Eidtmann H, et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole(ZO-FAST Study): final 60-month results. Ann Oncol 2013;24:398-405.
 
42 - Coleman RE (2010)
Coleman RE, Thorpe HC, Cameron D, et al. Adjuvant Treatment with Zoledronic Acid in Stage II/III Breast Cancer. The AZURE Trial (BIG 01/04). Cancer Res 2010;70(24 Suppl.): Abstract nr S4-5.
 
43 - Coles C (2016)
Coles C, Agarwal R, Ah-See ML, et al. Partial breast radiotherapy for women with early breast cancer: First results of local recurrence data for IMPORT LOW (CRUK/06/003). Eur J Cancer 2016;57:S4
 
44 - Collins LC (2005)
Collins LC, Tamimi RM, Baer HJ, et al. Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy: results from the Nurses' Health Study. Cancer. 2005 May 1;103(9):1778-84.
 
45 - Correa C (2017)
Correa C, Harris EE, Leonardi MC, et al. Accelerated Partial Breast Irradiation: Executive summary for the update of an ASTRO Evidence-Based Consensus Statement. Pract Radiat Oncol. 2017 Mar - Apr;7(2):73-79. doi: 10.1016/j.prro.2016.09.007. Epub 2016 Sep 17.
 
46 - Cortazar P (2014)
Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384:164-72.
 
47 - Couch FJ (2015)
Couch FJ, Hart SN, Sharma P, et al. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. J Clin Oncol. 2015 Feb 1;33(4):304-11. doi: 10.1200/JCO.2014.57.1414. Epub 2014 Dec 1.
 
48 - Cronin PA et al (2016)
Cronin PA et al. Impact of Age on Risk of Recurrence of Ductal Carcinoma In Situ: Outcomes of 2996 Women Treated with Breast-Conserving Surgery Over 30 Years. Ann Surg Oncol. 2016 Sep;23(9):2816-24.
 
49 - Cuzick J (2011)
Cuzick J, Sestak I, Pinder SE, et al. Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. Lancet Oncol. 2011 Jan;12(1):21-9.
 
50 - Cybulski C (2015)
Cybulski C. and the Polish Hereditary Breast Cancer Consortium. Clinical outcomes in women with breast cancer and a PALB2 mutation: a prospective cohort analysis. Lancet Oncol. 2015 Jun;16(6):638-44.
 
51 - Dall P (2015)
Dall P, Lenzen G Trastuzumab in the treatment of elderly patients with early breast cancer: Results from an observational study in Germany. J Geriatr Oncol. 2015 Nov;6(6):462-9
 
52 - Davies C (2013)
Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013; 381: 805-16. PMC3596060.
 
53 - de Korte MA (2007)
de Korte MA, EG de Vries et al. (111)Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: A clue to uncover the mechanisms of trastuzumab-related cardiotoxicity.Eur J cancer 2007; 14:2046-51
 
54 - Dekker TJ (2013)
Dekker TJ, Smit VT, Hooijer GK, et al. Reliability of core needle biopsy for determining ER and HER2 status in breast cancer. Ann Oncol. 2013 Apr;24(4):931-7.
 
55 - Derks MGM et al (2017)
Derks MGM et al. Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicenter, open-label, randomized phase 3 trial. Lancet Oncol 2017 in press
 
56 - Desmond A (2015)
Desmond A, Kurian AW, Gabree M et al. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment. JAMA Oncol. 2015 Oct;1(7):943-51. doi: 10.1001/jamaoncol.2015.2690.
 
57 - Diego EJ (2014)
Diego EJ, Soran A, McGuire KP, et al. Localizing high-risk lesions for excisional breast biopsy: a comparison between radioactive seed localization and wire localization. Ann SurgOncol. 2014;21(10):3268-72.
 
58 - Diel IJ (2008)
Diel IJ, Jaschke A, Solomayer EF, et al. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. Ann Oncol. 2008; 19:2007-11.
 
59 - Domchek SM (2010)
Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010 Sep 1;304(9):967-75
 
60 - Dominici LC (2010)
Dominici LC, Negron Gonzalez VM, Buzdar AU, et al. Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancer. Cancer 2010; 116(12):2884-9.
 
61 - Donker M (2015)
Donker M, Straver ME, Wesseling J, et al. Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: the MARI procedure. Ann Surg. 2015 Feb;261(2):378-82.
 
62 - Donker M (2023)
Donker M, van Tienhoven G, Straver M.E, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): A randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15(12):1303-10.
 
63 - Donker M (2014)
Donker M, Vrancken Peeters MJ, et al. Novel surgical technique to selectively remove metastatic axillary lymph nodes in breast cancer patients after neoadjuvant chemotherapy: The MARI procedure—Marking of the axilla with radioactive iodine seeds. Ann Surg. 2014 Apr 16.
 
64 - Dowsett M (2010)
Dowsett M, et al. Meta-analysis of breast cancer outcome in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 20100;28:509-18.
 
65 - Drooger JC (2015)
Drooger JC, Hooning MJ, Seynaeve CM, et al, Diagnostic and therapeutic ionizing radiation and the risk of a first and second primary breast cancer, with special attention for BRCA1 and BRCA2 mutation carriers: a critical review of the literature. Cancer Treat Rev. 2015 Feb;41(2):187-96. doi: 10.1016/j.ctrv.2014.12.002. Epub 2014 Dec 8.
 
66 - Easton DF (2015)
Easton DF, Pharoah PD, Antoniou AC, et al. Gene-panel sequencing and the prediction of breast-cancer risk. N Engl J Med. 2015 Jun 4;372(23):2243-57. doi: 10.1056/NEJMsr1501341. No abstract available.
 
67 - EBCTCG (2015)
EBCTCG: Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials: Lancet Oncology Volume 386, No. 10001, p1341–1352, 3 October 2015
 
68 - EBCTCG (2011)
EBCTCG: davies C, Godwin J, Gray R et al. relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomized trials. Lancet 2011; 378:771-784.
 
69 - EBCTCG (2014)
EBCTCG: Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials Lancet 2014
 
70 - EBCTCG (2011)
EBCTCG. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomized trials. Lancet 2011; 378: 771-84
 
71 - Erbes T (2014)
Erbes T, Orlowska-Volk M, ZurHausen A, et al. Neoadjuvant chemotherapy in breast cancer significantly reduces number of yielded lymph nodes by axillary dissection. BMC Cancer. 2014; 14: 4.
 
72 - Evans DG (2013)
Evans DG, Ingham SL, Baildam A, et al. Contralateral mastectomy improves survival in women with BRCA1/2-associated breast cancer. Breast Ca Res Treat 2013; 140: 135-142.
 
73 - Fakkert IE (2012)
Fakkert IE, Mourits MJ, et al. Breast Cancer Incidence After Risk-Reducing Salpingo-Oophorectomy in BRCA1 and BRCA2 Mutation Carriers. Cancer Prev Res (Phila) 2012 Nov;5(11):1291-1297.
 
74 - Fehrenbacher L (2000)
Fehrenbacher L Distant invasive breast cancer recurrence risk in human epidermal growth factor receptor 2-positive T1a and T1b node-negative localized breast cancer diagnosed from 2000 to 2006: a cohort from an integrated health care delivery system. J Clin Oncol. 2014 Jul 10;32(20):2151-8
 
75 - Finkelman BS (2012)
Finkelman BS, Rubinstein WS, Friedman S, et al.. Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriers. J Clin Oncol. 2012 Apr 20;30(12):1321-8. doi: 10.1200/JCO.2011.37.8133. Epub 2012 Mar 19.
 
76 - Fischer B (2001)
Fischer B, Dignam J, Bryant J, Wolmark N. Five years versus more than five years of tamoxifen for lymphnode-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 radomized trial. J Natl Cancer Inst. 2001; 93:684-690.
 
77 - Fisher B (1997)
Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J ClinOncol. 1997 Jul;15(7):2483-93.
 
78 - Fitzsullivan E (2013)
Fitzsullivan E, Lari SA, Smith B, et al. Incidence and consequence of close margins in patients with ductal carcinoma-in situ treated with mastectomy: is further therapy warranted? Ann Surg Oncol. 2013 Dec;20(13):4103-12.
 
79 - Fontein DB (2013)
Fontein DB, van de Water W, Mieog JS, et al. Timing of the sentinel lymph node biopsy in breast cancer patients receiving neoadjuvant therapy - recommendations for clinical guidance. Eur J SurgOncol. 2013 May;39(5):417-24
 
80 - Fontein DBY et al (2014)
Fontein DBY et al. Efficacy of six month neoadjuvant endocrine therapy in postmenopausal, hormone receptor-positive breast cance patients- A phase II trial. Eur J Cancer 2014;50:2190-2200.
 
81 - Forbes JF (2016)
Forbes JF, Sestak I, Howell A, et al; IBIS-II investigators Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial. Lancet. 2016 Feb 27;387(10021):866-73. doi: 10.1016/S0140-6736(15)01129-0. Epub 2015 Dec 11.
 
82 - Fostira F (2012)
Fostira F, Tsitlaidou M, Papadimitriou C, et al. Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study. Breast Cancer Res Treat. 2012 Jul;134(1):353-62. doi: 10.1007/s10549-012-2021-9. Epub 2012 Mar 21.
 
83 - Francis AM (2015)
Francis AM, Haugen CE, Grimes LM, et al. Is Sentinel Lymph Node Dissection Warranted for Patients with a Diagnosis of Ductal Carcinoma In Situ? Ann Surg Oncol. 2015 Dec;22(13):4270-9.
 
84 - Francis PA (2015)
Francis PA, Regan MM, Fleming GF, et al. Adjuvant ovarian suppression in premenopausal breast cancer. NEJM 2015; 372: 436-46.
 
85 - Freyer G (2011)
Freyer G, Campone M, Peron J, et al. Adjuvant docetaxel/cyclophosphamide in breast cancer patients over the age of 70: results of an observational study. CritRevOncolHematol. 2011 Dec;80(3):466-73.
 
86 - Fuster D (2008)
Fuster D, Duch J, Paredes P, et al. Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures. J ClinOncol. 2008 Oct 10;26(29):4746-51.
 
87 - Gail MH (1989)
Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989; 81: 1879-86.
 
88 - Galimberti V (2013)
Galimberti V, Cole BF, Zurrida S, et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol. 2013;14(4):297-305.
 
89 - Galimberti V (2016)
Galimberti V, Ribeiro Fontana SK, Maisonneuve P, et al. Sentinel node biopsy after neoadjuvant treatment in breast cancer: Five-year follow-up of patients with clinically node-negative or node-positive disease before treatment. Eur J SurgOncol. 2016 Mar;42(3):361-8.
 
90 - Gianni et al (2016)
Gianni et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol 2016;17:791-800.
 
91 - Gianni L et al (2012)
Gianni L et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012;13:25-32.
 
92 - Gianni L (2014)
Gianni L. Neoadjuvant and adjuvant trastuzumab in patiënts with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet Oncol 2014;15:640-7.
 
93 - Giuliano AE (2011)
Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs. no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. Jama. 2011;305(6):569-75.
 
94 - Giuliano AE (2010)
Giuliano AE, McCall L, Beitsch P, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg. 2010 Sep;252(3):426-32.
 
95 - Glechner A (2013)
Glechner A, Wockel A, Gartlehner G, et al. Sentinel lymph node dissection only versus complete axillary lymph node dissection in early invasive breast cancer: a systematic review and meta-analysis. Eur J Cancer. 2013;49(4):812-25.
 
96 - Gnant M (2009)
Gnant M et al: Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009;360:679-91.
 
97 - Gnant M (2015)
Gnant M, Mlineritsch B, Stoeger H, et al. Zolendronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrazol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast Cancer and Colorectal Cancer Study Group Trial 12. Ann Oncol 2015; 26: 313-20.
 
98 - Gobardhan PD (2013)
Gobardhan PD, de Wall LL, van der Laan L, et al. The role of radioactive iodine-125 seed localization in breast-conserving therapy following neoadjuvant chemotherapy. Ann Oncol. 2013;24(3):668-73.
 
99 - Goldhirsch A et al (2013)
Goldhirsch A et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 Ann of Oncol 2013;24: 2206
 
100 - Goldhirsch A (2013)
Goldhirsch A. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet. 2013 Sep 21;382(9897):1021-8.
 
101 - Gonzalez-Angulo AM (2011)
Gonzalez-Angulo AM, Timms KM, Liu S, et al. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res. 2011 Mar 1;17(5):1082-9. doi: 10.1158/1078-0432.CCR-10-2560. Epub 2011 Jan 13.
 
102 - Goss PE et al (2016)
Goss PE et al. Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years NEJM 2016;375:209-19.
 
103 - Goss PE (2003)
Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. The New England journal of medicine. 2003; 349: 1793-802.
 
104 - Gray R (1999)
Gray R, Davidson NE, et al. Locoregional failure 10 years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: experience of the Eastern Cooperative Oncology Group. J Clin Oncol. 1999; 17(6):1689-700.
 
105 - Gray RG
Gray RG, Rea D, Handley K et al. aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 woman with early breast cancer. J Clin Oncol 31 (suppl 15;5).
 
106 - Groen EJ (2017)
Groen EJ, Elshof LE, Visser LL, et al. Finding the balance between over- and under-treatment of ductal carcinoma in situ (DCIS). Breast. 2017 Feb;31:274-83
 
107 - Groheux D (2012)
Groheux D, Hindié E, Giacchetti S, et al. Triple-negative breast cancer: early assessment with 18F-FDG PET/CT during neoadjuvant chemotherapy identifies patients who are unlikely to achieve a pathologic complete response and are at a high risk of early relapse. J Nucl Med. 2012 Feb;53(2):249-54.
 
108 - Guerrero A (2013)
Guerrero A, Gavila J, Folkerd E et al. Incidence and predictors of ovarian function recovery (OFR) in breast cancer (BC) patients with chemotherapy-induced amenorrhea (CIA) who switched from tamoxifen to exemestane. Ann Oncol 2013; 24: 674-679.
 
109 - Hadji P (2016)
Hadji P, Coleman RE, Wilson C, et al.Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel. Ann Oncol 2016.
 
110 - Haloua MH (2016)
Haloua MH, Volders JH, Krekel NM, et al. Intraoperative Ultrasound Guidance in Breast-Conserving Surgery Improves Cosmetic Outcomes and Patient Satisfaction: Results of a Multicenter Randomized Controlled Trial (COBALT). Ann Surg Oncol. 2016 Jan;23(1):30-7.
 
111 - Hartman AR (2012)
Hartman AR, Kaldate RR, et al. Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer. Cancer. 2012 Jun 1;118(11):2787-95. doi: 10.1002/cncr.26576. Epub 2011 Oct 5.
 
112 - Hartogh MD den (2014)
Hartogh MD den, van den Bongard HJ, Davidson MT, et al. Full-thickness closure in breast-conserving surgery: the impact on radiotherapy target definition for boost and partial breast irradiation. A multimodality image evaluation. Ann Surg Oncol. 2014 Nov;21(12):3774-9. doi: 10.1245/s10434-014-3801-8. Epub 2014 May 30.
 
113 - Heemskerk-Gerritsen BA (2015)
Heemskerk-Gerritsen BA, Rookus MA, Aalfs CM, et al HEBON, Hooning MJ, Seynaeve C. improved overall survival after contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: a prospective analysis. Int J Cancer 2015 Feb 1; 136(3): 668-77 (2015B)
 
114 - Heemskerk-Gerritsen BA (2015)
Heemskerk-Gerritsen BA, Rookus MA, Aalfs CM, et al; HEBON, Hooning MJ, Seynaeve C. Improved overall survival after contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: a prospective analysis. Int J Cancer. 2015 Feb 1;136(3):668-77. doi: 10.1002/ijc.29032. Epub 2014 Jul 8.
 
115 - Heemskerk-Gerritsen BA (2015)
Heemskerk-Gerritsen BA, Seynaeve C, van Asperen CJ, et al. Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction. J Natl Cancer Inst 2015 Mar 18;107(5):10.1093/jnci/djv033.(2015 A)
 
116 - Hennequin C (2013)
Hennequin C, et al .Irradiation of Internal Mammary Nodes After Mastectomy. Int J Radiat ONcol Biol Phys 2013
 
117 - Hennessy BT (2005)
Hennessy BT, Hortobagyi GN, et al. Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J ClinOncol. 2005;23:9304-11.
 
118 - Henry NL (2013)
Henry NL, Xia R, Banerjee M et al. Predictors of recovery of ovarian function during aromatase inhibitor therapy. Ann Oncol 2013; 24: 2011-2016.
 
119 - Heuts EM et al (2009)
Heuts EM et al. Internal mammary lymph drainage and sentinel node biopsy in breast cancer - A study on 1008 patients. Eur J Surg Oncol. 2009 Mar;35(3):252-7. doi: 10.1016/j.ejso.2008.06.1493. Epub 2008 Aug 5.
 
120 - Hieken TJ (2013)
Hieken TJ, et al. Imaging response and residual metastatic axillary lymph node disease after neoadjuvant chemotherapy for primary breast cancer. Ann SurgOncol 2013; 20: 3199-3204.
 
121 - Hindié E (2012)
Hindié E, Groheux D, Hennequin C, et al. Lymphoscintigraphy can select breast cancer patients for internal mammary chain radiotherapy. Int J Radiat Oncol Biol Phys. 2012 Jul 15;83(4):1081-8. doi: 10.1016/j.ijrobp.2011.09.016.
 
122 - Hogan MP (2015)
Hogan MP, Goldman DA, Dashevsky B, et al. Comparison of 18F-FDG PET/CT for Systemic Staging of Newly Diagnosed Invasive Lobular Carcinoma Versus Invasive Ductal Carcinoma. J Nucl Med. 2015 Nov;56(11).
 
123 - Houssami N (2014)
Houssami N, Macaskill P, Marinovich ML, et al. The association of surgical margins and local recurrence in women with early-stage invasive breast cancer treated with breast-conserving therapy: a meta-analysis. Ann Surg Oncol. 2014 Mar;21(3):717-30.
 
124 - https://www (2016)
https://www.astro.org/News-and-Publications/News-and-Media-Center/News-Releases/2016/Updated-ASTRO-guideline-expands-pool-of-suitable-candidates-for-accelerated-partial-breast-irradiation/
 
125 - Hudis C (2007)
Hudis C.A. Trastuzumab-mechanism of action and use in clinical practice. NEJM 2007;357;39-51.
 
126 - Hughes JH (2008)
Hughes JH, Mason MC, Gray RJ, et al. A multi-site validation trial of radioactive seed localization as an alternative to wire localization. Breast J. 2008;14(2):153-7.
 
127 - Hughes KS (2013)
Hughes KS, et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol 2013;31:2382e7
 
128 - Humbert O (2015)
Humbert O, Riedinger JM, Charon-Barra C, et al. Identification of Biomarkers Including 18FDG-PET/CT for Early Prediction of Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer. Clin Cancer Res. 2015 Dec 15;21(24):5460-8.
 
129 - Hunt KK (2009)
Hunt KK, Yi M, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients. Ann Surg. 2009;250:558-66.
 
130 - Hwang et al (2013)
Hwang et al. The Comparative Study of Ultrasonography, Contrast-Enhanced MRI, and (18)F-FDG PET/CT for Detecting Axillary Lymph Node Metastasis in T1 Breast Cancer. J Breast Cancer. 2013 Sep;16(3):315-21.
 
131 - Ingle JN (2008)
Ingle JN, Tu D, Pater JL, Muss HB, Martino S, Robert NJ, et al. Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2008; 19: 877-82.
 
132 - Jackisch C (2015)
Jackisch C, Kim SB, Semiglazov V, et al. Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study. Ann Oncol. 2015 Feb;26(2):320-5.
 
133 - Jackson L (2014)
Jackson L, Bourke AG, Abdul Aziz F, et al. Radioactive seed localisation to guide removal of impalpable lymph nodes (radioguided occult lesion localisation using iodine-125 seeds, "ROLLIS"). BMJ Case Rep. 2014;2014.
 
134 - Jagsi R et al (2014)
Jagsi R et al. Radiation field design in the ACOSOG Z0011 (Alliance) Trial. J Clin Oncol. 2014 Nov 10;32(32):3600-6.
 
135 - Jakesz R (2007)
Jakesz R, Greil R, Gnant M, Schmid M, Kwasny W, Kubista E, et al. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. Journal of the National Cancer Institute. 2007; 99: 1845-53.
 
136 - Jin Y (2005)
Jin Y. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005;97:30-9.
 
137 - Joensuu H (2009)
Joensuu H, Bono P, Kataja V Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. J Clin Oncol. 2009 Dec 1;27(34):5685-92.
 
138 - Joensuu H. (2006)
Joensuu H. , P.L. Kellokumpu-lehtinen, P. Bono, R et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. NEJM 2006, 354:809-20.
 
139 - Joerger M (2011)
Joerger M, Thürlimann B, Huober J. Small HER2-positive, node-negative breast cancer: who should receive systemic adjuvant treatment? Ann Oncol. 2011 Jan;22(1):17-23.
 
140 - Johnson J (2016)
Johnson J, Esserman L, et al. Sentinel Lymph Node Mapping in Post-Mastectomy Chest Wall Recurrences: Influence on Radiation Treatment Fields and Outcome. Ann Surg Oncol. 2016 Mar;23(3):715-21
 
141 - Jones S (2009)
Jones S, Holmes FA, O'Shaughnessy J, et al. Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735. J ClinOncol. 2009 Mar 10;27(8):1177-83
 
142 - Khosla S (2007)
Khosla S et al: Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007 Oct;22(10):1479-91.
 
143 - Kirova YM (2010)
Kirova YM, Savignoni A, Sigal-Zafrani B, et al. Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature. Breast Cancer Res Treat. 2010 Feb;120(1):119-26. doi: 10.1007/s10549-009-0685-6. Epub 2009 Dec 24.
 
144 - Koolen BB et al (2017)
Koolen BB et al. Combined PET-CT and axillary lymph node marking with radioactive iodine seeds (MARI procedure) for tailored axillary treatment in node-positive breast cancer after neoadjuvant therapy. Br J Surg. 2017 Aug;104(9):1188-1196.
 
145 - Koolen BB (2013)
Koolen BB, Pengel KE, Wesseling J, et al. FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer. Breast. 2013 Oct;22(5):691-7.
 
146 - Koolen BB (2012)
Koolen BB, ValdesOlmos RA, Elkhuizen PHM, et al. Locoregional lymph node involvement on 18F-FDG PET/CT in breast cancer patients scheduled for neoadjuvant chemotherapy. Breast Cancer ResTreat 2012;135(1):231–40
 
147 - Koolen BB (2013)
Koolen BB, ValdésOlmos RA, Vogel WV, et al. Pre-chemotherapy 18F-FDG PET/CT upstages nodal stage in stage II-III breast cancer patients treated with neoadjuvant chemotherapy. Breast Cancer Res Treat. 2013 Sep;141(2):249-54.
 
148 - Koolen BB (2012)
Koolen BB, Vrancken Peeters MJ, Aukema TS, et al. RA.18F-FDG PET/CT as a staging procedure in primary stage II and III breast cancer: comparison with conventional imaging techniques. Breast Cancer Res Treat. 2012 Jan;131(1):117-26.
 
149 - Koolen BB (2012)
Koolen BB, Vrancken Peeters MJ, Wesseling J, et al. Association of primary tumour FDG uptake with clinical, histopathological and molecular characteristics in breast cancer patients scheduled for neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging. 2012 Dec;39(12):1830-8.
 
150 - Koolen et al (2013)
Koolen et al. Early Assessment of Axillary Response with 18F-FDG PET/CT during Neoadjuvant Chemotherapy in Stage II–III Breast Cancer: Implications for Surgical Management of the Axilla. Ann Surg Oncol (2013) 20:2227–2235; 2)
 
151 - Kotsopoulos J (2016)
Kotsopoulos J, Huzarski T, Gronwald J, et al; Hereditary Breast Cancer Clinical Study Group. Bilateral Oophorectomy and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. J Natl Cancer Inst. 2016 Sep 6;109(1). pii: djw177. doi: 10.1093/jnci/djw177. Print 2017 Jan
 
152 - Krag DN (2007)
Krag DN, Anderson SJ, Julian TB, et al; National Surgical Adjuvant Breast and Bowel Project.Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol. 2007 Oct;8(10):881-8.
 
153 - Krammer J (2015)
Krammer J, Schnitzer A, Kaiser CG, et al. (18)?F-FDG PET/CT for initial staging in breast cancer patients - Is there a relevant impact on treatment planning compared to conventional staging modalities? Eur Radiol. 2015 Aug;25(8):2460-9. doi: 10.1007/s00330-015-3630-6. Epub 2015 Feb 15.
 
154 - Krekel NM (2013)
Krekel NM, Haloua MH, Lopes Cardozo AM, et al. Intraoperative ultrasound guidance for palpable breast cancer excision (COBALT trial): a multicentre, randomised controlled trial. Lancet Oncol. 2013 Jan;14(1):48-54. doi: 10.1016/S1470-2045(12)70527-2. Epub 2012 Dec 4.
 
155 - Kuehn T (2013)
Kuehn T, Bauerfeind I, Fehm T, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013 Jun;14(7):609-18. doi: 10.1016/S1470-2045(13)70166-9. Epub 2013 May 15
 
156 - Kurian AW et al (2014)
Kurian AW et al. Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. J Clin Oncol. 2014 Jul 1;32(19):2001-9.
 
157 - Landercasper J (2017)
Landercasper J, Bennie B, Bray MS, Vang CA, Linebarger JH. Does neoadjuvant chemotherapy affect morbidity, mortality, reoperations, or readmissions in patients undergoing lumpectomy or mastectomy for breast cancer? Gland Surg. 2017 Feb;6(1):14-26.
 
158 - Leal F (2015)
Leal F, Liutti VT, Antunes dos Santos VC, et al. Neoadjuvant endocrine therapy for resectable breast cancer: A systematic review and meta-analysis. Breast. 2015 Aug;24(4):406-12.
 
159 - Leonardi MC (2013)
Leonardi MC, Maisonneuve P, Mastropasqua MG, et a. Accelerated partial breast irradiation with intraoperative electrons: using GEC-ESTRO recommendations as guidance for patient selection. Radiother Oncol. 2013 Jan;106(1):21-7
 
160 - Li J et al (2016)
Li J et al. Breast cancer genetic risk profile is differentially associated with interval and screen-detected breast cancers. Ann Oncol. 2016
 
161 - Liebens FP (2006)
Liebens FP, Carly B, Pastijn A, et al. Management of BRCA1/2 associated breast cancer: a systematic qualitative review of the state of knowledge in 2006. Eur J Cancer 2007;43:238-57.
 
162 - Litière S (2012)
Litière S, Werutsky G, Fentiman IS, et al. Breast conserving therapy versus mastectomy for stage I-II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial. Lancet Oncol. 2012 Apr;13(4):412-9. doi: 10.1016/S1470-2045(12)70042-6. Epub 2012 Feb 27.
 
163 - Liu FF (2015)
Liu FF, Shi W, Done SJ, et al. Identification of a Low-Risk Luminal A Breast Cancer Cohort That May Not Benefit From Breast Radiotherapy. J Clin Oncol. 2015 Jun 20;33(18):2035-40. doi: 10.1200/JCO.2014.57.7999. Epub 2015 May 11
 
164 - Livi L (2015)
Livi L, Meattini I, Marrazzo L, et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year survival analysis of a phase 3 randomised controlled trial. Eur J Cancer 2015;51:451e463.
 
165 - Livi L (2006)
Livi L, Paiar F, Simontacchi G, et al. Loco regional failure pattern after lumpectomy and breast irradiation in 4,185 patients with T1 and T2 breast cancer. Implications for nodal irradiation. Acta Oncol. 2006;45(5):564-70.
 
166 - Lovrics PJ (2011)
Lovrics PJ, Cornacchi SD, Vora R, et al. Systematic review of radioguided surgery for non-palpable breast cancer. Eur J SurgOncol. 2011;37(5):388-97.
 
167 - Luiten JD (2015)
Luiten JD, Beek MA, Voogd AC, et al. Iodine seed- versus wire-guided localization in breast-conserving surgery for non-palpable ductal carcinoma in situ. Br J Surg. 2015.
 
168 - Maaren MC van (2016)
Maaren MC van, de Munck L, de Bock GH, et al. 10 year survival after breast-conserving surgery plus radiotherapy compared with mastectomy in early breast cancer in the Netherlands: a population-based study. Lancet Oncol. 2016 Aug;17(8):1158-70. doi: 10.1016/S1470-2045(16)30067-5. Epub 2016 Jun 22.
 
169 - Madsen EV (2015)
Madsen EV, Aalders KC, van der Heiden-van der Loo M, Gobardhan PD, van Oort PM, van der Ent FW, Rutgers EJ, Valdés Olmes RA, Elias SG, van Dalen T Prognostic Significance of Tumor-Positive Internal Mammary Sentinel Lymph Nodes in Breast Cancer: A Multicenter Cohort Study. Ann Surg Oncol. 2015 Dec;22(13):4254-62. doi: 10.1245/s10434-015-4535-y. Epub 2015 Mar 26.
 
170 - Mamounas EP (2012)
Mamounas EP, Anderson SJ, Dignam JJ, et al. Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27. J ClinOncol. 2012;30:3960-6.
 
171 - Mamounas EP (2008)
Mamounas EP, Jeong JH, Wickerham DL, Smith RE, Ganz PA, Land SR, et al. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008; 26: 1965-71.
 
172 - Mamounas EP (2014)
Mamounas EP, Tang G, Liu Q. The importance of systemic therapy in minimizing local recurrence after breast-conserving surgery: the NASPB experience. JCO 2014; 110: 45-50
 
173 - Mamtani A (2016)
Mamtani A, Barrio AV, King TA, et al. How Often Does Neoadjuvant Chemotherapy Avoid Axillary Dissection in Patients With Histologically Confirmed Nodal Metastases? Results of a ProspectiveStudy. Ann SurgOncol (2016) 23:3467–3474.
 
174 - Marinovich ML (2015)
Marinovich ML, Houssami N, Macaskill P, et al. Accuracy of ultrasound for predicting pathologic response during neoadjuvant therapy for breast cancer. Int J Cancer. 2015 Jun 1;136(11):2730-7.
 
175 - Martin M (2005)
Martin M, Pienkowski T, Mackey J, et al; Breast Cancer International Research Group 001 Investigators. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005 Jun 2;352(22):2302-13.
 
176 - Mavaddat N (2013)
Mavaddat N, Peock S, Frost D, et al; EMBRACE. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst. 2013 Jun 5;105(11):812-22. doi: 10.1093/jnci/djt095. Epub 2013 Apr 29.
 
177 - Mavroudis D (2015)
Mavroudis D, Saloustros E, Malamos N. Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG). Ann Oncol. 2015 Jul;26(7):1333-40.
 
178 - McGhan LJ (2012)
McGhan LJ, Dueck AC, Gray RJ, et al. The changing landscape of axillary surgery: which breast cancer patients may still benefit from complete axillary lymph node dissection? J Surg Oncol 2012 Sep 1;106(3):254-9
 
179 - Meijnen P (2007)
Meijnen P, Oldenburg HS, Loo CE, et al. Risk of invasion and axillary lymph node metastasis in ductal carcinoma in situ diagnosed by core-needle biopsy. Br J Surg. 2007 Aug;94(8):952-6.
 
180 - Metcalfe K (2011)
Metcalfe K, Gershman S, Lynch HT, et al. Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. British Journal of Cancer , (12 April 2011) | doi:10.1038/bjc.2011.120.
 
181 - Metzger-Filho O (2013)
Metzger-Filho O et al. Patterns of Recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from international breast cancer study group trials VIII and IX. J Clin Oncol 2013; 31: 3083-3090.
 
182 - Meyer P (2012)
Meyer P, Landgraf K, Högel B, et al. BRCA2 mutations and triple-negative breast cancer. PLoS One. 2012;7(5):e38361. doi: 10.1371/journal.pone.0038361. Epub 2012 May 30.
 
183 - Monteau A (2009)
Monteau A, Sigal-Zafrani B, Kirova YM, et al. Ductal carcinoma in situ of the breast with close or focally involved margins following breast-conserving surgery: treatment with reexcision or radiotherapy with increased dosage. Int J Radiat Oncol Biol Phys. 2009 Nov 15;75(4):1021-8.
 
184 - Moran MS (2017)
Moran MS, Zhao Y, Ma S, Kirova Y Association of Radiotherapy Boost for Ductal Carcinoma In Situ With Local Control After Whole-Breast Radiotherapy. JAMA Oncol. 2017 Aug 1;3(8):1060-1068.
 
185 - Mougalian SS et al (2016)
Mougalian SS et al.Ten-Year Outcomes of Patients With Breast Cancer With Cytologically Confirmed Axillary Lymph Node Metastases and Pathologic Complete Response After Primary Systemic Chemotherapy. JAMA Oncol. 2016 Apr;2(4):508-16.
 
186 - Muendlein A (2015)
Muendlein A, Rohde BH, Gasser K, et al. Evaluation of BRCA1/2 mutational status among German and Austrian women with triple-negative breast cancer. J Cancer Res Clin Oncol. 2015 Nov;141(11):2005-12. doi: 10.1007/s00432-015-1986-2. Epub 2015 May 15.
 
187 - Mukesh MB (2012)
Mukesh MB, Barnett G, Cumming J, et al. Association of breast tumour bed seroma with post-operative complications and late normal tissue toxicity: results from the Cambridge Breast IMRT trial. Eur J Surg Oncol. 2012 Oct;38(10):918-24. doi: 10.1016/j.ejso.2012.05.008. Epub 2012 Jun 14.
 
188 - Näslund-Koch C (2016)
Näslund-Koch C, Nordestgaard BG, Bojesen SE. Increased Risk for Other Cancers in Addition to Breast Cancer for CHEK2*1100delC Heterozygotes Estimated From the Copenhagen General Population Study.J Clin Oncol. 2016 Apr 10;34(11):1208-16. doi: 10.1200/JCO.2015.63.3594. Epub 2016 Feb 16.
 
189 - National Research Council (2006)
National Research Council. Health risks from exposure to low levels of ionizing radiation: BEIR VII Phase 2. Washington, DC: The National Academies Press, 2006
 
190 - NCCN
NCCN guideline breast cancer
 
191 - Nguyen PL (2008)
Nguyen PL, Taghian AG, Katz MS, et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol 2008; 26: 2373-8.
 
192 - Norum J (2000)
Norum J, Andreassen T. Screening for metastatic disease in newly diagnosed breast cancer patients. What is cost-effective? Anticancer Res 2000; 20: 2193-6
 
193 - Nottegar A (2016)
Nottegar A, Veronese N, Senthil M, et al. Extra-nodal extension of sentinel lymph node metastasis is a marker of poor prognosis in breast cancer patients: A systematic review and an exploratory meta-analysis. Eur J Surg Oncol. 2016 Jul;42(7):919-25. doi: 10.1016/j.ejso.2016.02.259. Epub 2016 Mar 10.
 
194 - Obdeijn IM (2016)
Obdeijn IM, Heijnsdijk EAM, et al. Mammographic screening in BRCA1 mutation carriers postponed until age 40: evaluation of benefits, costs and radiation risks using models. Eur J C 2016;63:135-142.
 
195 - Obdeijn IM (2014)
Obdeijn IM, Winter-Warnars GAO, Mann RM, et al. Should we screen BRCA1 mutation carriers only with MRI? A multicenter study. Breast Cancer Res Treat 2014;144(3):577-82. DOI 10.1007/s10549-014-2888-8
 
196 - Olivotto I (2013)
Olivotto I, Whelan TJ, Parpia S, et al. Interim cosmetic and toxicity results from RAPID: A randomized trial of accelerated partial breast irradiation using 3D conformal external beam radiation therapy. J Clin Oncol 2013;31:4038e4045.
 
197 - O'Sullivan CC (2015)
O'Sullivan CC, Bradbury I, Campbell C. Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors = 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials. J Clin Oncol. 2015 Aug 20;33(24):2600-8.
 
198 - Ouldamer L (2016)
Ouldamer L, Bonastre J, Brunet-Houdard S, et al. Dead space closure with quilting suture versus conventional closure with drainage for the prevention of seroma after mastectomy for breast cancer (QUISERMAS): protocol for a multicentre randomised controlled trial. BMJ Open. 2016 Apr 4;6(4):e009903. doi: 10.1136/bmjopen-2015-009903
 
199 - Ouldamer L (2015)
Ouldamer L, Caille A, Giraudeau B, et al. Quilting Suture of Mastectomy Dead Space Compared with Conventional Closure with Drain. Ann Surg Oncol. 2015 Dec;22(13):4233-40. doi: 10.1245/s10434-015-4511-6. Epub 2015 Mar 18.
 
200 - Ozen M (2016)
Ozen M, Gunduz M, Ates O Trastuzumab 1-year vs 9-week in early-stage HER2-positive, lymph node negative breast cancer patients. J BUON. 2016 Jul-Aug;21(4):799-808.
 
201 - Pagani O (2014)
Pagani O, Reg Tan MM, Walley BA, et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. NEJM 2014; 371: 107-18.
 
202 - Palomba G (2014)
Palomba G, Budroni M, Olmeo N, et al. Triple-negative breast cancer frequency and type of BRCA mutation: Clues from Sardinia. Oncol Lett. 2014 Apr;7(4):948-952. Epub 2014 Jan 28.
 
203 - Pan H (2013)
Pan H, Wu N, Ding H, et al. Intraoperative ultrasound guidance is associated with clear lumpectomy margins for breast cancer: a systematic review and meta-analysis. PLoS One. 2013 Sep 20;8(9):e74028. doi: 10.1371/journal.pone.0074028. eCollection 2013
 
204 - Pengel KE (2014)
Pengel KE, Koolen BB, Loo CE, et al. Combined use of ¹8F-FDG PET/CT and MRI for response monitoring of breast cancer during neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging. 2014 Aug;41(8):1515-24.
 
205 - Pepels MJ (2013)
Pepels MJ, Vestjens JH, de Boer M, et al. Models predicting non-sentinel node involvement also predict for regional recurrence in breast cancer patients without axillary treatment. Eur J Surg Oncol. 2013 Dec;39(12):1351-7. doi: 10.1016/j.ejso.2013.09.006.
 
206 - Perez EA (2014)
Perez EA .Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol. 2014 Nov 20;32(33):3744-52
 
207 - Pern F (2012)
Pern F, Bogdanova N, Schürmann P, et al. Mutation analysis of BRCA1, BRCA2, PALB2 and BRD7 in a hospital-based series of German patients with triple-negative breast cancer. PLoS One. 2012;7(10):e47993. doi: 10.1371/journal.pone.0047993. Epub 2012 Oct 24.
 
208 - Petrelli F (2013)
Petrelli F, Coinu A, Cabiddu M, Ghilardi M, Lonati V, Barni S. Five or more years of adjuvant endocrine therapy in breast cancer: a meta-analysis of published randomised trials. Breast Cancer Res Treatm. 2013; 140: 233-40. 10.1007/s10549-013-2629-4.
 
209 - Phi X-A (2015)
Phi X-A, Houssami N, Obdeijn IM, et al. Magnetic Resonance imaging improves breast screening sensitivity in BRCA mutation carriers age = 50 Years: evidence from an individual patient data meta-analysis. J Clin Oncol 2015;33(4):349-356.
 
210 - Phi X-A (2016)
Phi X-A, Saadatmand S, de Bock GH, et al. Contribution of mammografie to MRI screening in BRCA mutation carriers by BRCA status and age: individual patient data meta-analysis. British Journal of Cancer 2016;114(6):631-7.
 
211 - Piccart MJ (2015)
Piccart MJ, Gingras I. Breast cancer in 2015: Academic research sheds light on issues that matter to patients. Nat Rev Clin Oncol. 2016 Feb;13(2):67-8
 
212 - Piccart-Gebhart MJ (2005)
Piccart-Gebhart MJ, Procter M, Leyland-Jones B. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005 Oct 20;353(16):1659-72.
 
213 - Pierce LJ (2010)
Pierce LJ, Phillips KA, Griffith KA, et al. Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy.Breast Cancer Res Treat. 2010 Jun;121(2):389-98. doi: 10.1007/s10549-010-0894-z. Epub 2010 Apr 22.
 
214 - Pijpe A (2012)
Pijpe A, Andrieu N, Easton DF, et al; GENEPSO; EMBRACE; HEBON. Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK). BMJ. 2012 Sep 6;345:e5660. doi: 10.1136/bmj.e5660.
 
215 - Pilewskie M (2014)
Pilewskie M, Olcese C, Eaton A, et al. Perioperative breast MRI is not associated with lower locoregional recurrence rates in DCIS patients treated with or without radiation. Ann Surg Oncol. 2014 May;21(5):1552-60.
 
216 - Pivot X (2013)
Pivot X et al. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. Lancet Oncol. 2013 Jul;14(8):741-8.
 
217 - Pivot X (2014)
Pivot X: Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study. Ann Oncol. 2014 Oct;25(10):1979-87
 
218 - Plecha D (2015)
Plecha D, Bai S, Patterson H, et al. Improving the Accuracy of Axillary Lymph Node Surgery in Breast Cancer with Ultrasound-Guided Wire Localization of Biopsy Proven Metastatic Lymph Nodes. Ann SurgOncol. 2015.
 
219 - Polgar C (2010)
Polgar C, Major T, Fodor J, et al. Accelerated partial-breast irradiation using high-dose-rate interstitial brachytherapy: 12-year update of a prospective clinical study. Radiother Oncol 2010;94:274e279.
 
220 - Poortmans P (2014)
Poortmans P. Postmastectomy radiation in breast cancer with one to three involved lymph nodes: ending the debate. Lancet. 2014 Jun 21;383(9935):2104-6.
 
221 - Poortmans PM (2017)
Poortmans PM, Arenas M, Livi L. Over-irradiation. Breast. 2017 Feb;31:295-302
 
222 - Poortmans PM (2015)
Poortmans PM, Collette S, Kirkove C, et al. Internal Mammary and Medial Supraclavicular Irradiation in Breast Cancer. N Engl J Med 2015;373(4):317-27.
 
223 - Postma EL (2012)
Postma EL, Verkooijen HM, van Esser S, et al. Efficacy of 'radioguided occult lesion localisation' (ROLL) versus 'wire-guided localisation' (WGL) in breast conserving surgery for non-palpable breast cancer: a randomised controlled multicentre trial. Breast Cancer ResTreat. 2012;136(2):469-78.
 
224 - Pouw B (2015)
Pouw B, de Wit-van der Veen LJ, Stokkel MP, et al. Heading toward radioactive seed localization in non-palpable breast cancer surgery? A meta-analysis. J SurgOncol. 2015 Feb;111(2):185-91.
 
225 - Powell SN (2003)
Powell SN, Kachnic. LA. Roles of BRCA1 and BRCA2 in homologous recombination, DNA replication fidelity and the cellular response to ionizing radiation. Oncogene 2003;22:5784-5791
 
226 - Powles T (2006)
Powles T, Paterson A, McCloskey E, et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Res. 2006;8(2):R13.
 
227 - Prendeville S (2015)
Prendeville S, Ryan C, Feeley L, et al. Sentinel lymph node biopsy is not warranted following a core needle biopsy diagnosis of ductal carcinoma in situ (DCIS) of the breast. Breast. 2015 Jun;24(3):197-200.
 
228 - Preston DL (2002)
Preston DL, Mattson A, Holmberg E, et al. Radiation effects on breast cancer risk: a pooled analysis of eight cohorts. Radiation Research 2002:158(2):220-235
 
229 - Prevos R (2012)
Prevos R, Smidt ML, Tjan-Heijnen VC, et al. Pre-treatment differences and early response monitoring of neoadjuvant chemotherapy in breast cancer patients using magnetic resonance imaging: a systematic review. EurRadiol. 2012 Dec;22(12):2607-16.
 
230 - Price J (2015)
Price J, Chen SW. Mammographically screen-detected asymmetric densities with architectural distortion and normal ultrasound at assessment: Value of MRI as a problem-solving tool. J Med Imaging RadiatOncol. 2015 Jun;59(3):312-9.
 
231 - Provencher L (2016)
Provencher L, Hogue JC, Desbiens C, et al. Is clinical breast examination important for breast cancer detection? Curr Oncol. 2016 Aug;23(4):e332-9. doi: 10.3747/co.23.2881. Epub 2016 Aug 12.
 
232 - Qvamme G (2015)
Qvamme G, Axelsson CK, Lanng C, et al. Randomized clinical trial of prevention of seroma formation after mastectomy by local methylprednisolone injection. Br J Surg. 2015;102(10):1195-203.
 
233 - Rakovitch E (2015)
Rakovitch E, Nofech-Mozes S, Hanna W, et al. A population-based validation study of the DCIS Score predicting recurrence risk in individuals treated by breast-conserving surgery alone. Breast Cancer Res Treat. 2015 Jul;152(2):389-98.
 
234 - Ram R (2014)
Ram R, Singh J, McCaig E. Sentinel Node Biopsy Alone versus Completion Axillary Node Dissection in Node Positive Breast Cancer: Systematic Review and Meta-Analysis. International Journal of Breast Cancer. 2014;513780.
 
235 - Rao R et al (2013)
Rao R et al. Axillary node interventions in breast cancer: a systematic review. Jama. 2013;310(13):1385-94.
 
236 - Rebbeck TR (2009)
Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 2009 Jan 21;101(2):80-87.
 
237 - Recht A (2016)
Recht A, Comen EA, Fine RE, et al. Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update. J ClinOncol. 2016 Dec 20;34(36):4431-4442.
 
238 - Renaudeau C (2016)
Renaudeau C, Lefebvre-Lacoeuille C, Campion L, et al. Evaluation of sentinel lymph node biopsy after previous breast surgery for breast cancer: GATA study. Breast. 2016 Aug;28:54-9.
 
239 - Riegger et al (2012)
Riegger et al. Comparison of the diagnostic value of FDG-PET/CT and axillary ultrasound for the detection of lymph node metastases in breast cancer patients. Acta Radiol. 2012 Dec 1;53(10):1092-8.
 
240 - Robertson L (2012)
Robertson L, Hanson H, Seal S, et al. BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years. Br J Cancer. 2012 Mar 13;106(6):1234-8. doi: 10.1038/bjc.2012.31. Epub 2012 Feb 14.
 
241 - Rodriguez N (2013)
Rodriguez N, Sanz X, Dengra J, et al. Five-year outcomes, cosmesis, and toxicity with 3-dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys 2013;87:1051e1057.
 
242 - Roeke T (2014)
Roeke T, van Bommel AC, Gaillard-Hemmink MP, et al. The additional cancer yield of clinical breast examination in screening of women at hereditary increased risk of breast cancer: a systematic review. Breast Cancer Res Treat. 2014 Aug;147(1):15-23. doi: 10.1007/s10549-014-3074-8. Epub 2014 Aug 8.
 
243 - Romond E (2005)
Romond E, Perez EA, Bryant J, et al. Doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab as adjuvant therapy for patients with HER-2 positive operable breast cancer: combined analysis of NSABP-B31/NCCTG-N9831. N Engl J Med 2005 353:1673-84.
 
244 - Rouanet P (2014)
Rouanet P, Roger P, Rousseau E. HER2 overexpression a major risk factor for recurrence in pT1a-bN0M0 breast cancer: results from a French regional cohort. Cancer Med. 2014 Feb;3(1):134-42. doi:
 
245 - Rummel S (2013)
Rummel S, Varner E, Shriver CD, et al. Evaluation of BRCA1 mutations in an unselected patient population with triple-negative breast cancer. Breast Cancer Res Treat. 2013 Jan;137(1):119-25. doi: 10.1007/s10549-012-2348-2. Epub 2012 Nov 29.
 
246 - Rusch P (2016)
Rusch P, Hoffmann O, Stickelmann AL, et al. Distant metastasis detected by routine staging in breast cancer patients participating in the national German screening programme: consequences for clinical practice. Springerplus. 2016 Jul 7;5(1):1010. doi: 10.1186/s40064-016-2703-6. eCollection 2016.
 
247 - Rusthoven CG (2016)
Rusthoven CG, Rabinovitch RA, Jones BL, et al. The impact of postmastectomy and regional nodal radiation after neoadjuvant chemotherapy for clinically lymph node-positive breast cancer: a National Cancer Database (NCDB) analysis. Ann Oncol. 2016 May; 27(5): 818-27.
 
248 - Ryden L (2016)
Ryden L, et al. Aromatase inhibitors alone or sequentially combined with tamoxifen in postmenopausal early breast cancer compared with tamoxifen or placebo - Meta-analyses on efficacy and adverse events based on randomized clinical trials. Breast 2016;26:106-14.
 
249 - Saadatmand S (2014)
Saadatmand S, Vos JR, Hooning MJ, et al. Relevance and efficacy of breast canecr screening in BRCA1 and BRCA2 mutation carriers above 60 years; a national cohort study. International Journal of Cancer 2014;135(12)2940-9.
 
250 - Saarto T (2004)
Saarto T, Vehmanen L, Virkkunen P, et al. Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol. 2004;43(7):650-6.
 
251 - Samant R (1999)
Samant R, Ganguly P. Staging investigations in patients with breast cancer: the role of bone scans and liver imaging. Arch Surg 1999; 134: 551-3.
 
252 - Sanders ME et al (2005)
Sanders ME et al. The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up. Cancer. 2005 Jun 15;103(12):2481-4
 
253 - Schipper RJ (2015)
Schipper RJ, Moossdorff M, Beets-Tan RGH, Smidt ML, Lobbes MBI. Noninvasive nodal restaging in clinically node positive breast cancer patients after neoadjuvant systemic therapy: a systematic review. Eur J Radiol. 2015 Jan;84(1):41-47.
 
254 - Schmidt MK (2016)
Schmidt MK, Hogervorst F, van Hien R, et al. Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers. J Clin Oncol. 2016 Aug 10;34(23):2750-60. doi: 10.1200/JCO.2016.66.5844. Epub 2016 Jun 6.
 
255 - Schmitz et al (2017)
Schmitz et al. Monitoring tumor response to neoadjuvant chemotherapy using MRI and 18F-FDG PET/CT in breast cancer subtypes. 2017 May 22;12(5):e0176782.
 
256 - Schneider BP (2015)
Schneider BP Pilot trial of paclitaxel-trastuzumab adjuvant therapy for early stage breast cancer: a trial of the ECOG-ACRIN cancer research group (E2198). Br J Cancer. 2015 Dec 22;113(12):1651-7.
 
257 - Schwentner L (2017)
Schwentner L, Helms G, Nekljudova V, et al. Using ultrasound and palpation for predicting axillary lymph node status following neoadjuvant chemotherapy - Results from the multi-center SENTINA trial. Breast. 2017 Feb;31:202-207.
 
258 - Senkus E et al (2015)
Senkus E et al. Primary Breast Cancer: ESMO Clinical Practice Guidelines ESMO guidelines. Ann Oncol (2015) 26 (suppl 5): v8-v30.
 
259 - Sestak I (2013)
Sestak I, Dowsett M et al. Factors predicting late recurrence for estrogen receptor-positive breast cancer. J Natl Cancer Inst 2013; 105: 1504-11.
 
260 - Shachar SS (2016)
Shachar SS, Hurria A, Muss HB. Breast Cancer in Women Older Than 80 Years. J Oncol Pract. 2016 Feb;12(2):123-32
 
261 - Shaikh T (2013)
Shaikh T, Narra V, Goyal S, et al. Lumpectomy closure technique does not affect dosimetry in patients undergoing external-beam-based accelerated partial breast irradiation. Ann Surg Oncol. 2013 Apr;20(4):1323-8. doi: 10.1245/s10434-012-2775-7. Epub 2012 Dec 11.
 
262 - Sharek D (2015)
Sharek D, Zuley ML, Zhang JY, et al. Radioactive seed localization versus wire localization for lumpectomies: a comparison of outcomes. AJR Am J Roentgenol. 2015;204(4):872-7.
 
263 - Sharma P (2014)
Sharma P, Klemp JR, Kimler BF, et al. Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing. Breast Cancer Res Treat. 2014 June; 145(3): 707–714. doi:10.1007/s10549-014-2980-0.
 
264 - Simos D (2015)
Simos D, Catley C, van Walraven C, et al. Imaging for distant metastases in women with early-stage breast cancer: a population-based cohort study. CMAJ. 2015 Sep 8;187(12):E387-97. doi: 10.1503/cmaj.150003. Epub 2015 Jun 22.
 
265 - Slamon D (2011)
Slamon D, Eiermann W, Robert N, et al, Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011 Oct 6;365(14):1273-83.
 
266 - Smith IE (2006)
Smith IE, Dowsett M, Yap YS et al. Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines. J Clin Oncol 2006; 24: 2444-2447.
 
267 - Smith L (2007)
Smith L, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007; 369:29-36.
 
268 - Solá M (2000)
Solá M, Alberro JA, Fraile M, et al. Complete axillary lymph node dissection versus clinical follow-up in breast cancer patients with sentinel node micrometastasis: final results from the multicenter clinical trial AATRM 048/13/2000. Annals of surgical oncology. 2013;20(1):120-7.
 
269 - Solin LJ et al (2013)
Solin LJ et al. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst. 2013 May 15;105(10):701-10. doi: 10.1093/jnci/djt067. Epub 2013 May 2.
 
270 - Soucy G (2008)
Soucy G, Bélanger J, Leblanc G, et al. Surgical margins in breast-conservation operations for invasive carcinoma: does neoadjuvant chemotherapy have an impact? J Am Coll Surg. 2008 Jun;206(6):1116-21.
 
271 - Spielmann M (2009)
Spielmann M, Roché H, Delozier T Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial. J Clin Oncol. 2009 Dec 20;27(36):6129-34.
 
272 - Staley H (2014)
Staley H, McCallum I, Bruce J. Postoperative Tamoxifen for ductal carcinoma in situ: Cochrane systematic review and meta-analysis. Breast. 2014 Oct;23(5):546-51
 
273 - Staley H (2012)
Staley H, McCallum I, Bruce J. Postoperative Tamoxifen for ductal carcinoma in situ: Cochrane systematic review. 2012 Oct;17(10)
 
274 - Stearns V ea (2003)
Stearns V ea. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 2003;95:1758-64.
 
275 - Stewart HJ et al (2001)
Stewart HJ et al. Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years. J Natl Cancer Inst 2001; 93: 456-62.
 
276 - Stewart HJ (2001)
Stewart HJ, Prescott RJ, Forrest AP. Scottisch adjuvant tamoxifen trial: a randomized study updated to 15 years. J Natl Cancer Inst 2001; 93:456-462
 
277 - Straver ME (2010)
Straver ME, Loo CE, Alderliesten T, et al. Marking the axilla with radioactive iodine seeds (MARI procedure) may reduce the need for axillary dissection after neoadjuvant chemotherapy for breast cancer. Br J Surg. 2010 Aug;97(8):1226-31.
 
278 - Straver ME (2009)
Straver ME, Rutgers EJ, Oldenburg HS, et al.. Accurate axillary lymph node dissection is feasible after neoadjuvant chemotherapy. Am J Surg. 2009 Jul;198(1):46-50.
 
279 - Strnad V (2016)
Strnad V, Ott OJ, Hildebrandt G, et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breastconserving surgery for low-risk invasive and in-situ carcinoma of the female breast: A randomised, phase 3, non-inferiority trial. Lancet 2016;387:229e238.
 
280 - Suter T (2007)
Suter T, Procter M, van Veldhuisen D, et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 2007; 25;3859-65
 
281 - Tang G (2014)
Tang G, Liu Q. The importance of systemic therapy in minimizing local recurrence after breast-conserving surgery: the NSABP experience. J Surg Oncol. 2014 Jul;110(1):45-50. doi: 10.1002/jso.23609.
 
282 - Taylor DB (2015)
Taylor DB, Bourke AG, Westcott E, et al. Radioguided occult lesion localisation using iodine-125 seeds ('ROLLIS') for removal of impalpable breast lesions: First Australian experience. J Med Imaging RadiatOncol. 2015;59(4):411-20.
 
283 - Teixeira et al (2016)
Teixeira et al. Additional Prone 18F-FDG PET/CT Acquisition to Improve the Visualization of the Primary Tumor and Regional Lymph Node Metastases in Stage II/III Breast Cancer. Clin Nucl Med 2016;41: 181–6.
 
284 - Teixeira et al (2017)
Teixeira et al. PET/CT with 18F-FDG predicts short-term outcome in stage II/III breast cancer patients upstaged to N2/3 nodal disease. Eur J Surg Oncol. 2017 Apr;43(4):625-635.
 
285 - Teixeira SC (2016)
Teixeira SC, Koolen BB, Elkhuizen PH, et al. PET/CT with 18F-FDG predicts short-term outcome in stage II/III breast cancer patients upstaged to N2/3 nodal disease. Eur J SurgOncol. 2016 Oct 31. pii: S0748-7983(16)30950-7.
 
286 - Telli ML (2007)
Telli ML, Hunt SA, Carlson RW, et al. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol 2007; 25:3525-33.
 
287 - Tevaarwerk AJ (2014)
Tevaarwerk AJ, Wang M, Zhao F, et al. Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2014; 32: 3948-58.
 
288 - Thompson ER et al (2015)
Thompson ER et al. Prevalence of PALB2 mutations in Australian familial breast cancer cases and controls. Breast Cancer Res. 2015 Aug 19;17(1):111.
 
289 - Thorsen LB (2016)
Thorsen LB, Offersen BV, Danø H, et al. DBCG-IMN: A Population-Based Cohort Study on the Effect of Internal Mammary Node Irradiation in Early Node-Positive Breast Cancer. J Clin Oncol. 2016 Feb 1;34(4):314-20. doi: 10.1200/JCO.2015.63.6456. Epub 2015 Nov 23.
 
290 - Tjan-Heijnen V (2017)
Tjan-Heijnen V et al. DATA study. In press 2017
 
291 - Tolaney SM (2015)
Tolaney SM, Barry WT, Dang CT, et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med. 2015 Jan 8;372(2):134-41.
 
292 - Tormey DC (1996)
Tormey DC, Gray R, Falkson HC. Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. Eastern Cooperative Oncology Group. J Natl Cancer Inst. 1996; 88: 1828-33.
 
293 - Tung N (2016)
Tung N, Domcheck SM, Stadler Z et al. Counselling framework for moderate-penetrance cancer-susceptibility mutations. Nat Rev Clin Oncol. 2016 Sep;13(9):581-8.
 
294 - Tyrer J (2004)
Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med 2004; 23: 1111-30
 
295 - Goss (2005)
Goss et al J Natl Cancer Institute 2005:97:1262-71 en Jin ea JCO 2012; 30: 718
 
296 - Valachis A (2014)
Valachis A, Nearchou AD, Lind P Surgical management of breast cancer in BRCA-mutation carriers: a systematic review and meta-analysis. Breast Cancer Res Treat. 2014 Apr;144(3):443-55. doi: 10.1007/s10549-014-2890-1. Epub 2014 Feb 25.
 
297 - Valachis A (2014)
Valachis A, Nearchou AD, Lind P. Surgical management of breast cancer in BRCA-mutation carriers: a systematic review and meta-analysis. Breast Cancer Res Treat. 2014 Apr;144(3):443-55. doi: 10.1007/s10549-014-2890-1. Epub 2014 Feb 25
 
298 - Valejo FA et al (2013)
Valejo FA et al. Volume of breast tissue excised during breast-conserving surgery in patients undergoing preoperative systemic therapy. Rev Bras GinecolObstet. 2013 May;35(5):221-5.
 
299 - van den Einden LC (2012)
van den Einden LC, Aben KK, Massuger LF, et al. Successful centralisation of patients with vulvar carcinoma: a population-based study in The Netherlands. Eur J Cancer. 2012 Sep;48(13):1997-2003. doi: 10.1016/j.ejca.2012.01.030. Epub 2012 Mar 1.
 
300 - van den Hoven I (2015)
van den Hoven I, Kuijt G, Roumen R, et al. A head to head comparison of nine tools predicting non-sentinel lymph node status in sentinel node positive breast cancer women. J Surg Oncol. 2015 Aug;112(2):133-8.
 
301 - van den Hoven I (2015)
van den Hoven I, van Klaveren D, Voogd AC, et al. A Dutch Prediction Tool to Assess the Risk of Additional Axillary Non-Sentinel Lymph Node Involvement in Sentinel Node-Positive Breast Cancer Patients. Clin Breast Cancer. 2015 Sep 21. pii: S1526-8209(15)00214-1. doi: 10.1016/j.clbc.2015.09.003.
 
302 - van der Noordaa ME (2015)
van der Noordaa ME, Pengel KE, Groen E, et al. The use of radioactive iodine-125 seed localization in patients with non-palpable breast cancer: a comparison with the radioguided occult lesion localization with 99m technetium. Eur J SurgOncol. 2015;41(4):553-8.
 
303 - Van Hellemond IEG (2017)
Van Hellemond IEG et al. Ovarian function recovery during anastrazole in breast cancer patients with chemotherapy-induced ovarian function failure. In press JNCI 2017
 
304 - van Leeuwen FE (2000)
van Leeuwen FE, Klokman WJ, Veer MB, et al. Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. J Clin Oncol. 2000 Feb;18(3):487-97.)
 
305 - van Nijnatten TJ (2017)
van Nijnatten TJ et al. A Novel Less-invasive Approach for Axillary Staging After Neoadjuvant Chemotherapy in Patients With Axillary Node-positive Breast Cancer by Combining Radioactive Iodine Seed Localization in the Axilla With the Sentinel Node Procedure (RISAS): A Dutch Prospective Multicenter Validation Study. Clin Breast Cancer. 2017 Aug;17(5):399-402.
 
306 - van Nijnatten TJ (2015)
van Nijnatten TJ, Schipper RJ, Lobbes MB, Nelemans PJ, Beets-Tan RG, Smidt ML. The diagnostic performance of sentinel lymph node biopsy in pathologically confirmed node positive breast cancer patients after neoadjuvant systemic therapy: A systematic review and meta-analysis Eur J Surg Oncol. 2015 Oct;41(10):1278-87.
 
307 - van Os NJ (2016)
van Os NJ, Roeleveld N Weemaes CM, et al. Health risks for ataxia-telangiectasia mutated heterozygotes: a systematic review, meta-analysis and evidence-based guideline. Clin Genet. 2016 Aug;90(2):105-17. doi: 10.1111/cge.12710. Epub 2016 Jan 20.
 
308 - van Ramshorst MS (2016)
van Ramshorst MS, van der Heiden-van der Loo M, Dackus GM, et al. The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer. Breast Cancer Res Treat. 2016 Jul;158(2):361-71.
 
309 - van Riet YE (2010)
van Riet YE, Maaskant AJ, Creemers GJ, et al. Identification of residual breast tumour localization after neo-adjuvant chemotherapy using a radioactive 125 Iodine seed. Eur J SurgOncol. 2010;36(2):164-9.
 
310 - van Roozendaal LM (2016)
van Roozendaal LM, Goorts B, Klinkert M, et al. Sentinel lymph node biopsy can be omitted in DCIS patients treated with breast conserving therapy. Breast Cancer Res Treat. 2016 Apr;156(3):517-25.
 
311 - Vaz-Luis I (2014)
Vaz-Luis I, Keating NL, Lin NU, et al. Duration and toxicity of adjuvant trastuzumab in older patients with early-stage breast cancer: a population-based study. J Clin Oncol. 2014 Mar 20;32(9):927-34.
 
312 - Veronesi U (2013)
Veronesi U, Orecchia R, Maisonneuve P, et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial. Lancet Oncol. 2013 Dec;14(13):1269-77. doi: 10.1016/S1470-2045(13)70497-2. Epub 2013 Nov 11.
 
313 - Vliek SB et al (2016)
Vliek SB et al. Adjuvant ibandronat in postmenopausal women with early breast cancer. SABCS 2016. Abstract S6-02
 
314 - Volders JH (2016)
Volders JH, Haloua MH, Krekel NM, et al.; “the nationwide network and registry of histo- and cytopathology in the Netherlands (PALGA)” Neoadjuvant chemotherapy in breast-conserving surgery - Consequences on margin status and excision volumes: A nationwide pathology study.Eur J SurgOncol. 2016 Jul;42(7):986-93.
 
315 - von Minckwitz G (2014)
von Minckwitz G et al, Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol. 2014 Jun;15(7):747-56.
 
316 - Von Minckwitz G (2012)
Von Minckwitz G. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J ClinOncol 2012;30:1796-804.
 
317 - Voogd AC (2014)
Voogd AC, Rutgers EJTh, Leeuwen FE van. Welke factoren beïnvloeden de kans op borstkanker? In: Volksgezondheid Toekomst Verkenning, Nationaal Kompas Volksgezondheid. Bilthoven: RIVM, 2014: Nationaalkompas.nl
 
318 - Vos JR (2015)
Vos JR, Hsu L, Brohet RM, et al. Bias Correction Methods Explain Much of the Variation Seen in Breast Cancer Risks of BRCA1/2 Mutation Carriers. J Clin Oncol. 2015 Aug 10;33(23):2553-62. doi: 10.1200/JCO.2014.59.0463. Epub 2015 Jul 6.
 
319 - Vrieling C (2016)
Vrieling C, van Werkhoven E, Maingon P et al, European Organisation for Research and Treatment of Cancer, Radiation Oncology and Breast Cancer Groups. Prognostic Factors For Local Control in Breast Cancer After Long-term Follow-up in the EORTC Boost vs No Boost Trial: A Randomized Clinical Trial. JAMA Oncol. 2016 Sep 8. doi: 10.1001/jamaoncol.2016.3031. [Epub ahead of print]
 
320 - Vriens BE (2013)
Vriens BE, Aarts MJ, de Vries B, et al; Breast Cancer Trialists' Group of the Netherlands (BOOG).Doxorubicin/cyclophosphamide with concurrent versus sequential docetaxel as neoadjuvant treatment in patients with breast cancer. Eur J Cancer. 2013 Oct;49(15):3102-10.
 
321 - Vriens BE (2016)
Vriens BE, de Vries B, Lobbes MB, et al; INTENS Study Group. Ultrasound is at least as good as magnetic resonance imaging in predicting tumour size post-neoadjuvant chemotherapy in breast cancer. Eur J Cancer. 2016 Jan;52:67-76.
 
322 - Waaijer L (2015)
Waaijer L, Willems SM, Verkooijen HM, et al. Impact of preoperative evaluation of tumour grade by core needle biopsy on clinical risk assessment and patient selection for adjuvant systemic treatment in breast cancer. Br J Surg. 2015 Aug;102(9):1048-55.
 
323 - Wang Z (2011)
Wang Z, Wu L-C, Chen J-Q. Sentinel lymph node biopsy compared with axillary lymph node dissection in early breast cancer: a meta-analysis. Breast Cancer Res Treat. 2011;129(3):675-89.
 
324 - Watts NB (2010)
Watts NB, Diab DL. Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab. 2010 Apr;95(4):1555-65.
 
325 - Weischer M et al (2008)
Weischer M et al. CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls. J Clin Oncol. 2008 Feb 1;26(4):542-8.
 
326 - Whelan TJ et al (2015)
Whelan TJ et al. Regional Nodal Irradiation in Early-Stage Breast Cancer. N Engl J Med. 2015;373(4):307-16.
 
327 - Wolde B ten (2014)
Wolde B ten, van den Wildenberg FJ, Keemers-Gels ME, et al. Quilting prevents seroma formation following breast cancer surgery: closing the dead space by quilting prevents seroma following axillary lymph node dissection and mastectomy. Ann Surg Oncol. 2014 Mar;21(3):802-7. doi: 10.1245/s10434-013-3359-x. Epub 2013 Nov 12
 
328 - Wolff AC (2013)
Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J ClinOncol. 2013 Nov 1;31(31):3997-4013.
 
329 - Wong-Brown MW (2015)
Wong-Brown MW, Meldrum CJ, Carpenter JE, et al. Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer. Breast Cancer Res Treat. 2015 Feb;150(1):71-80. doi: 10.1007/s10549-015-3293-7. Epub 2015 Feb 15.
 
330 - Woo S-B et al (2006)
Woo S-B et al.. Systematic review: Bisphosphonates and osteonecrosis of the jaws. Ann Int Med 2006; 144:753-61.
 
331 - Yan S (2015)
Yan S, Li K, Jiao X, Zou H. Tamoxifen with ovarian function suppression versus tamoxifen alone as an adjuvant treatment for premenopausal breast cancer: a meta-analysis of published randomized controlled trials. Onco Targets Ther 2015; 8: 1433-41
 
332 - Yang Y et al (2012)
Yang Y et al. CHEK2 1100delC variant and breast cancer risk in Caucasians: a meta-analysis based on 25 studies with 29,154 cases and 37,064 controls. Asian Pac J Cancer Prev. 2012;13(7):3501-5.
 
333 - Yates L (2012)
Yates L, Kirby A, Crichton S, et al. Risk factors for regional nodal relapse in breast cancer patients with one to three positive axillary nodes. Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):2093-103.
 
334 - Yi M (2012)
Yi M, Meric-Bernstam F, Kuerer HM, et al. Evaluation of a breast cancer nomogram for predicting risk of ipsilateral breast tumor recurrences in patients with ductal carcinoma in situ after local excision. J Clin Oncol. 2012 Feb 20;30(6):600-7. doi: 10.1200/JCO.2011.36.4976. Epub 2012 Jan 17.